Madagascar vs Senegal: Statin use vs. average non-HDL cholesterol levels
Madagascar
2.9
in 2018
Senegal
2.9
in 2018
Madagascar rank
154th
Senegal rank
154th
Statin use vs. average non-HDL cholesterol levels over time
- Madagascar
- Senegal
How they compare
Madagascar currently reports 2.9 against 2.9 in Senegal, a difference of 0.
The two have swapped places 2 times across 39 shared years of data; in 1980 it was Senegal ahead.
Madagascar ranks 154th and Senegal ranks 154th of 191 countries.
Across the 4 decades both report, Madagascar averaged higher in 1 and Senegal in 3.
Head to head by decade
| Decade | Madagascar | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.45 | 2.62 | 0.17 | Senegal |
| 1990s | 2.58 | 2.7 | 0.12 | Senegal |
| 2000s | 2.68 | 2.72 | 0.04 | Senegal |
| 2010s | 2.82 | 2.81 | 0.0111 | Madagascar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Madagascar or Senegal?
- Madagascar, at 2.9 against 2.9 in Senegal as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Madagascar and Senegal?
- 0, with Madagascar ahead.
- How many years of comparable data are there for Madagascar and Senegal?
- 39 years are reported by both, from 1980 to 2018.
- How do Madagascar and Senegal rank globally for statin use vs. average non-hdl cholesterol levels?
- Madagascar ranks 154th and Senegal ranks 154th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.